| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue r... |
| 16 Oct 2026 |
8-K: Other Events
As previously announced, MiMedx Group, Inc., a Florida corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanara MedTech Inc., a Texas corporation (“Sanara”), and Mustang Merger Sub, I... |
| 29 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Reiterates Full Year Financial Outlook on a Standalone Basis |
| 29 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
AGREEMENT AND PLAN OF MERGERdated as ofJuly 29, 2026amongSANARA MEDTECH INC.,MIMEDX GROUP, INC.andMUSTANG MERGER SUB, INC. |
| 16 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Section 1. Principal and Registered Offices. The principal office of MiMedx Group, Inc. (the “Corporation”) shall be located at such place as the Board of Directors may specify from time to time. The Corporation shall have and continuous... |
| 29 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue r... |
| 16 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
EXHIBIT 99.1 MIMEDX Announces Restructuring and Cost Reduction Initiative Company Expects to Realize Annualized Savings of Approximately $40 Million MARIETTA, Ga., April 16, 2026 -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Com... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 m... |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue r... |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MIMEDX Announces Record Revenue for Third Quarter 2025 Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted ... |
| 03 Sep 2025 |
8-K: Regulation FD Disclosure
Cantor Global Healthcare Conference September 3, 2025 Investor Presentation |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year Second Quarter GAAP Net Income and Diluted Earnings... |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2025, the Company held its 2025 Annual Meeting of Shareholders (the “2025 Annual Meeting”). |
| 13 May 2025 |
8-K: Regulation FD Disclosure
BofA Securities 2025 Health Care Conference May 2025 Investor Presentation |
| 30 Apr 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter |
| 27 Feb 2025 |
8-K: Regulation FD Disclosure
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statem... |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year |
| 14 Jan 2025 |
8-K: Regulation FD Disclosure
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statem... |
| 16 Dec 2024 |
8-K: Entry into a Material Definitive Agreement
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , between MIMEDX GROUP, INC., a Florida corporation (the “Company”), and (“Indemnitee”). |
| 18 Nov 2024 |
8-K: Regulation FD Disclosure
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statem... |
Loading...